Moderna's personalized mRNA cancer vaccine, Intismeran (V940·mRNA-4157), has shown positive results in Phase 3 clinical trials, leading to a dramatic surge in the company's stock price. Investors in South Korea are expressing optimism, stating that "mRNA technology has finally been applied to cancer treatment."
So, can the cancer vaccine truly succeed? And how high can Moderna's stock rise?
Is the cancer vaccine truly successful?
The results are significant.
Intismeran, co-developed by Moderna and Merck, analyzes a patient's tumor to identify unique characteristics of cancer cells, allowing for the creation of a personalized mRNA vaccine. This vaccine informs the immune system about the cancer cell features, prompting it to attack.
In the Phase 3 trial, Intismeran was administered alongside Keytruda to high-risk melanoma patients who had undergone tumor removal. The results showed positive outcomes in key metrics, including recurrence-free survival and distant metastasis-free survival.
Thus, it is reasonable to conclude that the cancer vaccine has demonstrated actual effectiveness in clinical trials.
However, it is premature to claim that cancer has been conquered.
The current findings pertain specifically to melanoma patients and do not imply effectiveness across all cancer types. Long-term survival rates, detailed clinical data, and the actual therapeutic impact on patients still require further investigation.
What does the future hold for Moderna's stock?
The stock outlook is more complex.
Following the announcement of the successful Phase 3 trial, Moderna's stock skyrocketed by over 100% in a single day. Given that expectations for the cancer vaccine have already been factored into the stock price, there is a high likelihood of profit-taking adjustments in the short term.
This surge may also have been amplified by short sellers closing their positions, contributing to a so-called short squeeze.
Therefore, it is likely that the stock will not continue to rise in a straight line but will undergo corrections following the initial spike, with future direction dependent on clinical data and FDA approval.
However, the long-term narrative could be different.
If Intismeran receives FDA approval and is successfully commercialized, Moderna could be redefined from a COVID-19 vaccine company to a personalized cancer treatment firm. If positive results are also observed in other cancers, such as lung cancer, the company's valuation could be further reassessed.
Ultimately, three key factors will determine Moderna's stock trajectory: the strength of Intismeran's detailed clinical results, the speed of FDA approval, and the ability to demonstrate similar effects in other cancer types.
If these factors progress smoothly, the current surge could mark the beginning of a long-term reassessment of Moderna's corporate value rather than just a fleeting theme.
Conversely, if the detailed data falls short of expectations or if issues arise during the approval and commercialization process, the stock could significantly retrace its gains.
In conclusion, Moderna's success in Phase 3 trials represents a crucial first step in proving its potential. For investors, the key point to watch will be whether this cancer vaccine can transcend being just a new drug and become a new growth driver for Moderna.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.